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Abstract. Survivin is a member of the inhibitor of apoptosis 
family, which has been suggested to be crucial in the control 
of cell division and inhibition of apoptosis. Expression of 
this protein has been observed in transformed cell lines and 
human tumor tissues, including those from colorectal cancer, 
but not in terminally differentiated adult tissues. Survivin 
mRNA expression has frequently been detected in hepa-
tocellular carcinoma (HCC) and its protein expression has 
been demonstrated to be highly correlated with proliferation 
index rather than apoptotic index. The present study aimed 
to analyze the effect of survivin on the tumorigenicity and 
chemosensitivity of HCC via the establishment of an HCC cell 
line (PLC/PRF/5) with the stable knockdown of the survivin 
gene (PLC‑k3). This cell line displayed significantly lower 
rates of survival and proliferation in assays of cell viability and 
proliferation, respectively, compared with those of the control 
cell line (PLC-v). In addition, PLC-k3 cells were more sensi-
tive to cisplatin treatment, resulting in S phase arrest. These 
findings were further confirmed by an in vivo experiment. The 
data of the present study suggest that survivin is critical in 
promoting cell proliferation but not in inhibition of apoptosis, 
and enhances the chemosensitivity of HCC. Thus, the suppres-
sion of survivin expression in combination with cisplatin may 
contribute to the development of more effective treatments for 
HCC.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common 
type of cancer in males and the seventh most common type 
of cancer in females, with a total of 0.7 million new cases 
worldwide in 2008. HCC is the second and the sixth most 
common cause of cancer-related mortalities in males and 
females, respectively, with >0.5 million mortalities worldwide 
in 2008 (1). Due to the low five‑year survival rate following 
surgery and the frequent chemoresistance that is observed in 
patients with HCC, the development of an effective treatment 
is required.
Survivin, encoded by the gene BIRC5, is a member 
of the inhibitor of apoptosis protein family, and has been 
implicated in the control of cell division and the inhibition 
of apoptosis (2,3). It inhibits apoptosis through binding with 
caspase-9, and accelerates mitotic activity via association with 
microtubules of the mitotic spindle in the G2/M phase (4,5). 
Survivin has been demonstrated to be selectively expressed 
during embryonic development, but with low or no expres-
sion in terminally differentiated adult tissues (6,7). However, 
re-expression of the protein has been displayed in transformed 
cell lines and various types of human tumor tissues (6,8). In 
addition, survivin expression is correlated with poor prognosis 
in various types of cancer, such as lung adenocarcinoma (8) 
and colorectal cancer (10,11). In patients with HCC, tumor 
tissues have been demonstrated to express survivin mRNA 
(87.5%), whereas no expression was detected in normal liver 
tissues and tissues from non-tumor areas (12). Survivin expres-
sion has also been demonstrated to be highly correlated with 
proliferation index in HCC (12-15). Due to the possible roles 
of survivin in the suppression of apoptosis and promotion of 
proliferation in tumor tissues, survivin was widely recognized 
as a critical therapeutic target. It is therefore hypothesized 
that survivin depletion leads to cell cycle arrest, reduction of 
cell proliferation, induction of apoptosis and increased drug 
sensitivity. These factors may prove critical for the develop-
ment of cancer therapies. Therefore, the current study aimed 
to demonstrate the effect of survivin depletion on cell viability 
and tumor growth in HCC in vitro and in vivo.
Materials and methods
Cell culture. The HCC cell line (PLC/PRF/5; ATCC, Manassas, 
VA, USA) was maintained in Dulbecco's modified Eagle's 
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum at 37˚C in a 95% humidified incubator 
containing 5% CO2.
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Cell transfection with antisense survivin. The pEGFP vector 
containing the antisense version of the survivin full-length 
coding sequence (OriGene, Rockville, MD, USA) was 
confirmed by sequencing, using an ABI Prism 3100 Genetic 
analyzer (Applied Biosystems, Foster City, CA, USA). 
The plasmid was transfected into the PLC/PRF/5 cells 
using FuGene® 6 Transfection reagent (Roche Diagnostics, 
Indianapolis, IN, USA). The PLC/PRF/5 cells stably transfected 
with the survivin antisense sequence or empty pEGFP-N1 
vectors (Clontech Laboratories, Mountain View, CA, USA) 
were maintained by continuous G418 (Roche Diagnostics) 
drug selection. Expression of the survivin gene was confirmed 
with western blot analysis of the stably transfected cells. 
Clones with the successfully transfected antisense sequence 
(PLC-k3) and empty vectors alone (PLC-v) were then used for 
further in vitro and in vivo analysis.
Treatment with cisplatin. In order to determine the effect of 
survivin depletion on drug sensitivity, PLC-k3 and PLC-v cells 
were treated with 3.5 mg/ml cisplatin for 24 and 48 h. A cell 
proliferation assay, Annexin V apoptotic assay, and cell cycle 
analysis were then performed as subsequently described.
Cell proliferation assay. The proliferation rates of the untreated 
and cisplatin-treated PLC-k3 and PLC-v cells were determined 
by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma, St. Louis, MO, USA) cell proliferation 
assay. Cells were plated at 6,000 cells/well in 96-well culture 
plates. The MTT assay was performed at 0, 24, 48, 72 and 96 h 
on the untreated cells and at 24 and 48 h after treatment on the 
cisplatin-treated cells. Viability was assessed with the addi-
tion of MTT solution (1 mg/ml) and an average absorbance of 
570 nm was determined from triplicate samples.
In addition, a trypan blue exclusion assay was performed to 
quantify the viable cells in the untreated and cisplatin-treated 
PLC-k3 and PLC-v cell groups. Cells were seeded at 
2x104 cells/well in 24-well plates. A trypan blue exclusion 
assay was performed at 0, 24, 48 and 72 h on untreated cells 
and at 24 and 48 h after treatment on cisplatin-treated cells 
by staining the trypsinized cells with 0.4% trypan blue. 
The number of unstained cells (viable cells) from triplicate 
samples was recorded using a hemocytometer (Marienfeld, 
Lauda-Königshofen, Germany).
Annexin V apoptotic assay. The effect of survivin depletion on 
cellular apoptosis was determined by the Annexin V PE and 
7AAD Apoptosis Detection kit (BD Biosciences, San Jose, CA, 
USA) according to the manufacturer's instructions. Briefly, 
the untreated or the cisplatin-treated PLC-k3 and PLC-v cells 
were harvested, washed with phosphate-buffered saline, and 
stained with the Annexin V/7AAD mixture in binding buffer 
from the kit for 15 min at room temperature in the dark. The 
percentages of apoptotic cells were then determined using a 
FACSCalibur flow cytometer (BD Biosciences).
Cell cycle analysis. The untreated and cisplatin-treated 
PLC‑k3 and PLC‑v cells were harvested and fixed in cold 
70% ethanol at ‑20˚C for 24 h. Fixed cells were then washed 
and incubated in 0.2 mg/ml propidium iodide and 0.2 mg/ml 
RNase A at 37˚C for 30 min in the dark. The labeled cells were 
subjected to the FACSCalibur flow cytometer for cell cycle 
distribution analysis. The percentage of cells in each phase 
was analyzed using ModFit LT software (Verity Software 
House, Inc., Topsham, ME, USA).
Immunoblotting. PLC-k3 and PLC-v cells were then lysed in 
ice-cold radio-immunoprecipitation assay buffer containing 
150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 0.25% (w/v) 
sodium deoxycholate, 1 mM phenylmethanesulfonyl fluoride, 
and 1 U protease inhibitor cocktail (Roche Diagnostics, 
Penzberg, Germany) in 50 mM Tris-HCl buffer, pH 7.4. Equal 
amounts of protein were loaded onto an SDS-polyacrylamide 
gel under reducing conditions for gel electrophoresis and then 
transferred to a polyvinylidine fluoride membrane (Amersham 
Biosciences, Piscataway, NJ, USA). Blots were probed with 
the following antibodies: Anti-survivin rabbit polyclonal 
antibody (Calbiochem, San Diego, CA, USA), Anti-cyclin A 
rabbit polyclonal antibody, cyclin B1 rabbit polyclonal anti-
body and cyclin D1 rabbit polyclonal antibody (Cell Signaling 
Technology, Danvers, MA, USA), and the expression of 
β-actin (β-actin mouse monoclonal antibody; Sigma-Aldrich, 
St. Louis, MO, USA) was used as a loading control. After 
probing with horseradish peroxidase-conjugated secondary 
antibodies, membranes were developed with the Immobilon 
Western Chemiluminescent HRP Substrate system (Millipore, 
Billerica, MA, USA). The signals were then captured by the 
ChemiDoc XRS+ system (Bio-Rad, Hercules, CA, USA) and 
analyzed using Image Lab (Bio-Rad).
In vivo studies. Experiments involving animals were approved 
by the Committee on the Use of Live Animals for Teaching 
and Research, University of Hong Kong (Hong Kong, China; 
no. 1731-08). BALB/c-nu/nu (nude) mice (Charles River 
Laboratories, Wilmington, MA, USA) were maintained in 
laminar flow cabinets under pathogen‑free conditions, and all 
efforts were made to reduce suffering. PLC-k3 and PLC-v cells 
were harvested from mid-log phase cultures, and 1.5x106 cells 
were injected into the mice subcutaneously in order to induce 
xenograft tumor formation. Two weeks post-injection, the 
mice were randomly divided into the following 4 groups 
with 6 mice in each: PLC-v-(control), PLC-v-(cisplatin), 
PLC-k3-(control) and PLC-k3-(cisplatin). Cisplatin or saline 
(3 mg/kg) was administered intraperitoneally twice a week 
for 28 days. Caliper measurement of tumor dimensions was 
performed twice a week to estimate tumor size, with the 
formula 0.5 x l x w2 where l is the length and w is the width of 
the tumor. Mice were sacrificed with sodium pentobarbitone 
(150 mg/kg) overdose on day 42.
Statistical analysis. Data are presented as the mean ± stan-
dard deviation of three independent experiments for the 
in vitro study, and from six mice for the in vivo study. Data 
were analyzed using one-way analysis of variance, and 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Knockdown of the survivin gene in the PLC/PRF/5 cells. 
The pEGFP vector containing the antisense sequence of the 
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survivin gene was transfected into PLC/PRF/5 cells for func-
tional experiments. Immunoblotting analysis of the PLC-v 
and PLC-k3 cells demonstrated the successful knockdown of 
survivin expression in the PLC-k3 cells (Fig. 1A).
Survivin depletion reduces viability of PLC/PRF/5 cells. The 
effect of survivin depletion on cell viability was examined 
with an MTT assay. In 96 h, the average absorbance of the 
PLC-v cells increased by 2-fold, while it increased by 40% 
in the PLC-k3 cells. The rate of the increase in the number of 
viable cells in the PLC‑v group was significantly higher than 
that in PLC-k3 group (Fig. 1B).
In addition, a trypan blue assay was performed to quantify 
the viable cells in the PLC-v and PLC-k3 groups (Fig. 1C). The 
doubling time was 26.3 and 42.0 h for the PLC-v and PLC-k3 
cells, respectively. The PLC‑k3 cells demonstrated a signifi-
cantly lower number of viable cells compared with that of the 
PLC-v cells at 48 (26% lower) and 72 h (31% lower).
In order to determine whether cellular apoptosis or cell 
cycle progression contributed to the difference in the viability 
of the PLC-v and PLC-k3 cells, an Annexin V apoptotic 
assay and cell cycle analysis were performed. The results 
of the apoptotic assay indicated no significant difference 
in the percentages of early apoptotic PLC-v and PLC-k3 
cells (Fig. 1D). The analysis of cell cycle progression revealed 
that the PLC-k3 group exhibited 8.12% more cells in the G1 
phase and 9.89% fewer cells in the S phase, compared with 
those of the PLC-v group (Fig. 1E). This difference in cell 
cycle progression may contribute to the lower cell viability of 
the PLC-k3 cells.
The expression of cyclin D1, A and B1 was also investi-
gated by immunoblotting. Reduced expression levels of cyclin 
D1, A and B1 were observed in the PLC-k3 cells compared 
with those in the PLC-v cells (Fig. 1F).
Survivin depletion enhances cisplatin sensitivity. The effect 
of survivin depletion on cisplatin sensitivity was also exam-
ined. The PLC-k3 and PLC-v cells were treated with cisplatin 
for 24 and 48 h and an MTT cell proliferation assay was 
performed (Fig. 2A). When cells were treated for 24 h, cisplatin 
did not exert any effect on the viability of the PLC-v cells 
compared with that of the untreated cells, whereas a significant 
reduction of 45% was observed in the viability of the cispl-
atin-treated PLC-k3 cells compared with that of the untreated 
PLC‑k3 cells. Following the 48‑h treatment, a significant reduc-
tion was observed in the viability of the cisplatin-treated PLC-v 
cells (21% vs. the untreated PLC-v cells), and the cisplatin-treated 
PLC-k3 cells (47% vs. the untreated PLC-k3 cells).
Similarly, a trypan blue assay was performed to quantify 
the viable PLC-v and PLC-k3 cells following cisplatin treat-
ment (Fig. 2B). Following the 24‑h treatment, a significant 
reduction in the number of viable cells was observed in the 
cisplatin-treated PLC-v group (27% vs. the untreated PLC-v 
cells) and the cisplatin-treated PLC-k3 group (33% vs. the 
untreated PLC-k3 cells). Following the 48-h treatment, 
a significant reduction in the number of viable cells was 
observed in the cisplatin-treated PLC-v group (42% vs. the 
untreated PLC-v cells) and the cisplatin-treated PLC-k3 group 
(67% vs. the untreated PLC-k3 cells). Therefore, the results 
of the trypan blue assay were in agreement with those of the 
MTT assay in demonstrating that the PLC-k3 cells were more 
sensitive to cisplatin treatment than the PLC-v cells.
In order to determine whether cellular apoptosis contributed 
to the differences in the viability of the PLC-v and PLC-k3 cells 
with cisplatin treatment, an Annexin V apoptotic assay was 
performed (Fig. 2C). Increases in the percentages of early 
apoptotic cells were observed in the PLC-v and PLC-k3 groups 
when treated with cisplatin. Following the 24-h treatment, 
a significant increase in the number of early apoptotic cells 
Figure 1. (A) Representative blot displaying the expression of survivin in different clones of PLC/PRF/5 cells. The viability of PLC-v and PLC-k3 cells was 
studied by (B) MTT assay and (C) trypan blue assay. Results are presented as the mean ± standard deviation of three separate experiments. *P<0.05 PLC-v vs. 
PLC-k3 at the respective time point. Bar charts summarizing the percentages of PLC-v and PLC-k3 cells (D) in early apoptosis and (E) distributed in each 
phase of the cell cycle. Results are presented as the mean ± standard deviation of three separate experiments. *P<0.05 PLC-v vs. PLC-k3 at the respective phase. 
(F) Representative blot displaying the expression of cyclin D1, A and B1 in PLC-v and PLC-k3 cells. β-actin was used as a loading control.
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was observed in the cisplatin-treated PLC-v group (36% vs. 
the untreated PLC-v group) and the cisplatin-treated PLC-k3 
group (38% vs. the untreated PLC-k3 group). Following the 
48‑h treatment, a significant increase of 100% was observed 
in the PLC-v and PLC-k3 cisplatin-treated groups compared 
with the untreated PLC-v and PLC-k3 groups. Therefore, there 
was no significant difference in the levels of cisplatin‑induced 
apoptosis between the PLC-v and PLC-k3 cells at either 24 or 
48 h.
To study the effect of survivin depletion in cisplatin 
treatment on cell cycle progression, flow cytometric analysis 
was performed. Cell cycle distributions of the PLC-v and 
PLC-k3 were analyzed (Fig. 2D). When cells were treated for 
24 h, no significant difference in the distribution of the cell 
cycle stages was observed. However, changes in the cell cycle 
progression of the PLC-v and PLC-k3 cells were observed 
when treated for 48 h. In the PLC-v group, the distribution 
of cells was shifted from the G1 phase to the S phase with 
cisplatin treatment (a 1.6-fold increase in the percentage 
of cells in the S phase vs. the untreated cells). As for the 
PLC-k3 cells, a more marked shift of cells from the G1 and 
G2 phases to the S phase was observed with cisplatin treatment 
(a 2.28-fold increase in the percentage of cells in the S phase 
vs. the untreated PLC-k3 cells). Therefore, cisplatin treatment 
arrested cells in the S phase and the accumulation of cells was 
more profound in the survivin-depleted group.
Tumorigenicity of HCC cells with knockdown of the survivin 
gene in vivo. For the in vivo experiments, subcutaneous injec-
tion of the PLC-v and PLC-k3 cells was performed (Fig. 3A). 
The PLC-v cells successfully induced tumor growth in all mice 
Figure 2. Following treatment with cisplatin, the viability, early apoptosis and cell cycle distribution of PLC-v and PLC-k3 cells were studied. Bar charts 
summarizing cell viability analyzed by (A) MTT assay and (B) trypan blue assay. The percentage of PLC-v and PLC-k3 cells (C) in early apoptosis and 
(D) distributed in each phase of the cell cycle. Results are presented as the mean ± standard deviation of three separate experiments. *P<0.05 vs. untreated 
PLC-v cells and **P<0.05 vs. untreated PLC-k3 at the respective time point.
  A
  C
  B
  D
Figure 3. Survivin depletion of PLC/PRF/5 cells inhibits subcutaneous tumor 
formation. (A) Representative images of mice demonstrating the sizes of tumors 
formed with/without treatment with cisplatin, 42 weeks post-subcutaneous 
injection of PLC-v or PLC-k3 cells. (B) Graph summarizing tumor sizes in 
PLC-v- and PLC-k3-inoculated mice with/without cisplatin treatment. Results 
are presented as the mean ± standard deviation of tumor sizes in six mice in the 
PLC-v groups and the PLC-k3 (cisplatin) group, and as the mean of tumor sizes 
in 2 mice in the PLC-k3 (control) group. *P<0.05 vs. PLC-v (control) group.
  A
  B
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(12/12 mice), whereas the PLC-k3 cells only induced tumor 
growth in 2 of the 12 mice. In the PLC-v (control) group, the 
tumors grew rapidly and reached an average size of 500 mm3 
prior to day 40 (Fig. 3B). In the PLC-k3 (control) group, the 
tumors only became visible after day 28 and grew much more 
slowly than those in the PLC-v (control) group. Thus, survivin 
depletion cannot only inhibit the growth of cells in vitro, but 
also prevent tumor growth in vivo.
For the cisplatin treatment groups, cisplatin was admin-
istered starting on day 14, and significantly inhibited tumor 
growth in the mice in the PLC-v (cisplatin) group from day 28 
compared with that in the PLC-v (control) group. As the 
PLC-k3 cells induced tumors in only 2 mice and the tumors 
grew too slowly, no difference in the tumor size with cisplatin 
treatment was observed by 42 days post-cell injection.
Discussion
HCC is a common type of cancer worldwide and the develop-
ment of an effective treatment for HCC is required. Although 
chemotherapeutic drugs provide HCC patients with prolonged 
survival, chemoresistance often occurs. Thus, identification 
of the key components of tumorigenesis and chemoresistance 
in HCC may provide useful information on the molecular 
mechanisms of hepatocarcinogenesis and chemosensitivity. 
These components may serve as therapeutic targets of future 
treatments for HCC.
Survivin, which is differentially expressed in tumors 
compared with that in normal adult tissues, has been suggested 
to be associated with poor survival rates in several types of 
cancer, including non-small cell lung cancer (16), colorectal 
cancer (10) and neuroblastoma (17). Increased survivin expres-
sion has also been associated with poor prognostic parameters 
and outcomes in HCC (18). Therefore, survivin may be impor-
tant during tumorigenesis and in controlling chemosensitivity 
in HCC. In the present study, depletion of survivin in an HCC 
cell line (PLC-k3) was used to demonstrate its role in tumori-
genesis and chemosensitivity in HCC.
The survivin-depleted cells were demonstrated to have 
a significantly lower viability and longer doubling time than 
those of the control cells. This implies that survivin depletion 
could inhibit cell growth and survival in vitro. The difference 
in cell viability between the PLC-k3 and PLC-v groups may 
be due to either the change in cellular apoptosis and/or changes 
in cell cycle progression. In the Annexin V apoptosis assay, no 
differences between the levels of early apoptotic cells in the 
PLC-k3 and PLC-v groups were observed. This implies that 
knockdown of survivin did not enhance the apoptotic activity 
of HCC cells. Therefore, this may not be the main cause of the 
reduced cell viability in HCC, demonstrating that it differs from 
the response in other cancer cell lines, including cervical (19) 
and lung (20) cancers. However, the result is concordant with 
the findings of Ito et al (12) and Pizem et al (13) that survivin 
expression does not correlate with the apoptotic index of HCC 
tissues. These studies suggest that the oncogenic role of survivin 
may act through different pathways in different types of cancer.
Through cell cycle analysis in the current study, it was 
demonstrated that survivin depletion led to cell cycle arrest 
with a reduction in the S phase population. Cell cycle arrest 
in the PLC-k3 cells is also supported by the downregulation 
of the expression levels of cyclins D1 and A. Cyclin D1 is a 
G1 protein, while cyclin A is produced in the G1 phase and is 
essential for the G1/S transition (21,22). The downregulation of 
cyclins D1 and A reflects that cells were blocked at G1 phase 
and did not enter S phase. Thus, knockdown of survivin 
alone caused cell cycle arrest. The findings are concordant 
with those of a previous study which demonstrated that 
overexpression of survivin caused an increase in the S phase 
cell population (23). This consolidates the observation of the 
present study that survivin knockdown inhibited proliferation 
of PLC/PRF/5 cells via induction of cell cycle arrest.
Findings of the current study suggest that the knockdown 
of survivin is more critical in inhibiting cell proliferation 
than in inducing apoptosis. These results are consistent with 
those of previous studies stating a strong correlation between 
survivin expression and cell proliferation, but not apoptosis, in 
HCC (12-15). Previous studies have reported that survivin is 
essential in maintaining mitosis through stabilizing microtu-
bules and mediates the targeting of the chromosomal passenger 
complex to the centromere. Thus, it is an important protein for 
controlling normal cell division via participation in chromo-
somal segregation and cytokinesis (24,25). This explains the 
results in the present study demonstrating that knockdown of 
survivin hinders cell division and mitosis, and therefore leads 
to cell cycle arrest. 
In the present study, depletion of survivin in HCC cells was 
also demonstrated to enhance the effects of cisplatin in vitro. 
A lower number of viable cells and a shorter reaction time 
to cisplatin treatment were observed in the PLC-k3 group, 
suggesting that the PLC-k3 cells are more sensitive to cisplatin 
treatment compared with the PLC-v cells. This finding is 
consistent with a previous study that demonstrated survivin 
overexpression protected gastric cancer cells from cisplatin 
treatment, while a mutant form of survivin sensitized the cells 
to it (26). Thus, survivin may be critical in chemosensitivity 
to cisplatin in HCC cells. In addition, S phase arrest was 
observed in the PLC-v and PLC-k3 cells following cisplatin 
treatment in the present study. This is consistent with the 
findings of several previous studies on other types of cancer 
cell that chemotherapeutic drugs, including cisplatin, caused 
growth arrest in the S phase (27-29). The extent of the increase 
in number of cells accumulated in the S phase being higher 
in the PLC-k3 group than that in the PLC-v group following 
cisplatin treatment further demonstrated the higher sensitivity 
of the PLC-k3 cells to cisplatin-induced growth arrest in the 
S phase compared with that of the PLC-v cells.
In the present study, experiments in an animal model further 
confirmed the findings of the in vitro studies, that survivin 
depletion inhibits cell growth and proliferation. It is therefore 
suggested that survivin is essential for carcinogenesis in HCC. 
However, the effect of survivin depletion on chemosensitivity 
could not be demonstrated in the in vivo model due to the low 
success rate of tumor induction in the PLC-k3 group.
In summary, knockdown of survivin in an HCC cell line 
reduced cell viability by inhibition of cellular proliferation via 
cell cycle arrest rather than induction of early apoptosis. The 
findings were in agreement with those of previous studies which 
demonstrated that survivin was highly associated with cell 
proliferation index in primary tumors (12-15). Cisplatin exerted 
an additive growth inhibitory effect on PLC/PRF/5 cells with 
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survivin depletion in the present study by arresting the cells in 
the S phase of the cell cycle. Thus, knockdown of survivin may 
enhance the chemosensitivity of PLC/PRF/5 cells, implying that 
survivin overexpression may be critical in chemoresistance of 
HCC. These findings provide a novel therapeutic strategy for 
the effective treatment of patients with HCC that exhibit chemo-
resistance. Furthermore, patients will benefit from the reduced 
dosage of cisplatin necessary to produce chemotherapeutic 
results when survivin is downregulated.
Acknowledgements
This study was supported by the Small Project Grant 
(200707176035) of the University of Hong Kong and the 
Collaborative Research Fund (HKU5/CRF/08) of the Research 
Grants Council, Hong Kong, SAR, P.R. China.
References
 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: 
Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
 2. LaCasse EC, Baird S, Korneluk RG and MacKenzie AE: The 
inhibitors of apoptosis (IAPs) and their emerging role in cancer. 
Oncogene 17: 3247-3259, 1998.
 3. Altieri DC and Marchisio PC: Survivin apoptosis: an interloper 
between cell death and cell proliferation in cancer. Lab Invest 79: 
1327-1333, 1999.
 4. Reed JC: The Survivin saga goes in vivo. J Clin Invest 108: 
965-969, 2001.
 5. Geske FJ and Gerschenson LE: The biology of apoptosis. 
Hum Pathol 32: 1029-1038, 2001.
 6. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis 
gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 
917-921, 1997.
 7. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J and 
Altieri DC: Developmentally regulated expression of the novel 
cancer anti-apoptosis gene survivin in human and mouse differ-
entiation. Am J Pathol 152: 43-49, 1998.
 8. Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin 
inhibits caspase activity and apoptosis induced by Fas (CD95), 
Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 
1998.
 9. Sun PL, Jin Y, Kim H, et al: Survivin expression is an inde-
pendent poor prognostic marker in lung adenocarcinoma but not 
in squamous cell carcinoma. Virchows Arch 463: 427-436, 2013.
10. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and 
Tanigawa N: Inhibition of apoptosis by survivin predicts shorter 
survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 
1998.
11. Krieg A, Werner TA, Verde PE, Stoecklein NH and Knoefel WT: 
Prognostic and clinicopathological significance of survivin in 
colorectal cancer: a meta-analysis. PLoS One 8: e65338, 2013.
12. Ito T, Shiraki K, Sugimoto K, et al: Survivin promotes cell 
proliferation in human hepatocellular carcinoma. Hepatology 31: 
1080-1085, 2000.
13. Pizem J, Marolt VF, Luzar B and Cör A: Proliferative and 
apoptotic activity in hepatocellular carcinoma and surrounding 
non-neoplastic liver tissue. Pflugers Arch 442 (6 Suppl 1): 
R174-R176, 2001.
14. Ikeguchi M, Hirooka Y and Kaibara N: Quantitative analysis of 
apoptosis-related gene expression in hepatocellular carcinoma. 
Cancer 95: 1938-1945, 2002.
15. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y and Kaibara N: 
Inducible nitric oxide synthase and survivin messenger RNA 
expression in hepatocellular carcinoma. Clin Cancer Res 8: 
3131-3136, 2002.
16. Monzó M, Rosell R, Felip E, et al: A novel anti-apoptosis gene: 
Re-expression of survivin messenger RNA as a prognosis marker 
in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999.
17. Nakagawara A: Molecular basis of spontaneous regression of 
neuroblastoma: role of neurotrophic signals and genetic abnor-
malities. Hum Cell 11: 115-124, 1998.
18. Fields AC, Cotsonis G, Sexton D, Santoianni R and Cohen C: 
Survivin expression in hepatocellular carcinoma: correlation 
with proliferation, prognostic parameters, and outcome. 
Mod Pathol 17: 1378-1385, 2004.
19. Ambrosini G, Adida C, Sirugo G and Altieri DC: Induction of 
apoptosis and inhibition of cell proliferation by survivin gene 
targeting. J Biol Chem 273: 11177-11182, 1998.
20. Olie RA, Simões-Wüst AP, Baumann B, et al: A novel antisense 
oligonucleotide targeting survivin expression induces apoptosis 
and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 
2805-2809, 2000.
21. Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G: 
Cyclin A is required at two points in the human cell cycle. 
EMBO J 11: 961-971, 1992.
22. Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch 
in actively proliferating cells. Curr Opin Cell Biol 15: 158-163, 
2003.
23. Suzuki A, Hayashida M, Ito T, et al: Survivin initiates cell cycle 
entry by the competitive interaction with Cdk4/p16(INK4a) and 
Cdk2/cyclin E complex activation. Oncogene 19: 3225-3234, 
2000.
24. Vong QP, Cao K, Li HY, Iglesias PA and Zheng Y: Chromosome 
alignment and segregation regulated by ubiquitination of 
survivin. Science 310: 1499-1504, 2005.
25. Vader G, Kauw JJ, Medema RH and Lens SM: Survivin 
mediates targeting of the chromosomal passenger complex to the 
centromere and midbody. EMBO Rep 7: 85-92, 2006.
26. Nakamura M, Tsuji N, Asanuma K, et al: Survivin as a predictor 
of cis-diamminedichloroplatinum sensitivity in gastric cancer 
patients. Cancer Sci 95: 44-51, 2004.
27. Wang X, Wong SC, Pan J, et al: Evidence of cisplatin-induced 
senescent-like growth arrest in nasopharyngeal carcinoma cells. 
Cancer Res 58: 5019-5022, 1998.
28. Joe AK, Liu H, Suzui M, Vural ME, Xiao D and Weinstein IB: 
Resveratrol induces growth inhibition, S-phase arrest, apoptosis, 
and changes in biomarker expression in several human cancer 
cell lines. Clin Cancer Res 8: 893-903, 2002.
29. Lee BJ, Chon KM, Kim YS, et al: Effects of cisplatin, 5‑fluoro-
uracil, and radiation on cell cycle regulation and apoptosis in the 
hypopharyngeal carcinoma cell line. Chemotherapy 51: 103-110, 
2005.
